Cognition and MRI Markers in MS Patients With Aubagio® Treatment
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Multiple Sclerosis - Relapsing Remitting
- Type
- Interventional
- Phase
- Not Applicable
- Design
- Allocation: Non-RandomizedIntervention Model: Parallel AssignmentMasking: None (Open Label)Primary Purpose: Diagnostic
Participation Requirements
- Age
- Between 18 years and 60 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT03768648
- Collaborators
- Genzyme, a Sanofi Company
- Investigators
- Principal Investigator: Aurélie RUET, Prof CHU Bordeaux